Alterity Therapeutics Completes Phase 2 ATH434 Trial and Prepares for Phase 3 in MSA

Reuters

Jan 21

<a href="https://laohu8.com/S/ATH.AU">Alterity Therapeutics</a> Completes Phase 2 ATH434 Trial and Prepares for Phase 3 in MSA

Alterity Therapeutics Ltd. announced the successful completion of its Phase 2 program for its lead asset, ATH434, in multiple system atrophy $(MSA)$. The company reported that results from the Phase 2 trials demonstrated ATH434 to be safe and well-tolerated, with strong signals of efficacy in an indication that currently has no approved disease-modifying treatments. Alterity stated it is now advancing ATH434 towards a pivotal Phase 3 clinical program in MSA, targeting entry into an estimated $2.4 billion market opportunity. The company outlined three key objectives for 2026: finalizing the regulatory strategy to initiate the Phase 3 trial, deepening external engagement, and expanding intellectual property protection. An End-of-Phase 2 meeting with the FDA is planned for mid-2026, which will be the final regulatory step before the Phase 3 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9629287-en) on January 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2605510436"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605510436\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605510436?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-21 20:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605510436","market":"fut","top_or_hot":-1,"title":"Alterity Therapeutics Completes Phase 2 ATH434 Trial and Prepares for Phase 3 in MSA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ATH.AU\">Alterity Therapeutics</a> Completes Phase 2 ATH434 Trial and Prepares for Phase 3 in MSA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alterity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd. announced the successful completion of its Phase 2 program for its lead asset, ATH434, in multiple system atrophy <a href=\"https://laohu8.com/S/MSA\">$(MSA)$</a>. The company reported that results from the Phase 2 trials demonstrated ATH434 to be safe and well-tolerated, with strong signals of efficacy in an indication that currently has no approved disease-modifying treatments. Alterity stated it is now advancing ATH434 towards a pivotal Phase 3 clinical program in MSA, targeting entry into an estimated $2.4 billion market opportunity. The company outlined three key objectives for 2026: finalizing the regulatory strategy to initiate the Phase 3 trial, deepening external engagement, and expanding intellectual property protection. An End-of-Phase 2 meeting with the FDA is planned for mid-2026, which will be the final regulatory step before the Phase 3 trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9629287-en) on January 21, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alterity Therapeutics Completes Phase 2 ATH434 Trial and Prepares for Phase 3 in MSA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlterity Therapeutics Completes Phase 2 ATH434 Trial and Prepares for Phase 3 in MSA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-21 20:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ATH.AU\">Alterity Therapeutics</a> Completes Phase 2 ATH434 Trial and Prepares for Phase 3 in MSA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alterity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd. announced the successful completion of its Phase 2 program for its lead asset, ATH434, in multiple system atrophy <a href=\"https://laohu8.com/S/MSA\">$(MSA)$</a>. The company reported that results from the Phase 2 trials demonstrated ATH434 to be safe and well-tolerated, with strong signals of efficacy in an indication that currently has no approved disease-modifying treatments. Alterity stated it is now advancing ATH434 towards a pivotal Phase 3 clinical program in MSA, targeting entry into an estimated $2.4 billion market opportunity. The company outlined three key objectives for 2026: finalizing the regulatory strategy to initiate the Phase 3 trial, deepening external engagement, and expanding intellectual property protection. An End-of-Phase 2 meeting with the FDA is planned for mid-2026, which will be the final regulatory step before the Phase 3 trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9629287-en) on January 21, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL56jMRF:1","article_id":"2605510436","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605510436","pubTimestamp":1768998316,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alterity Therapeutics Ltd. announced the successful completion of its Phase 2 program for its lead asset, ATH434, in multiple system atrophy . The company reported that results from the Phase 2 trials demonstrated ATH434 to be safe and well-tolerated, with strong signals of efficacy in an indication that currently has no approved disease-modifying treatments. Alterity stated it is now advancing ATH434 towards a pivotal Phase 3 clinical program in MSA, targeting entry into an estimated $2.4 billion market opportunity. The company outlined three key objectives for 2026: finalizing the regulatory strategy to initiate the Phase 3 trial, deepening external engagement, and expanding intellectual property protection. An End-of-Phase 2 meeting with the FDA is planned for mid-2026, which will be the final regulatory step before the Phase 3 trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK7067":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","ATH.AU":"ALTERITY THERAPEUTICS LTD","BK4112":"金融交易所和数据","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"Alterity Therapeutics完成ATH434 2期试验并为MSA 3期做准备","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ATH.AU":0.9},"content_text":"Alterity Therapeutics Completes Phase 2 ATH434 Trial and Prepares for Phase 3 in MSA\n    \n\n        Alterity Therapeutics Ltd. announced the successful completion of its Phase 2 program for its lead asset, ATH434, in multiple system atrophy $(MSA)$. The company reported that results from the Phase 2 trials demonstrated ATH434 to be safe and well-tolerated, with strong signals of efficacy in an indication that currently has no approved disease-modifying treatments. Alterity stated it is now advancing ATH434 towards a pivotal Phase 3 clinical program in MSA, targeting entry into an estimated $2.4 billion market opportunity. The company outlined three key objectives for 2026: finalizing the regulatory strategy to initiate the Phase 3 trial, deepening external engagement, and expanding intellectual property protection. An End-of-Phase 2 meeting with the FDA is planned for mid-2026, which will be the final regulatory step before the Phase 3 trial.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9629287-en) on January 21, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}